PAREXEL International Corp. has appointed several executives to its global team of late phase and observational research experts in its PACE (Peri-Approval Clinical Excellence) group. The team will help sponsors collect the data they need to meet commercialization goals.

Peggy Schrammel will serve as vice president and global head portfolio management, PACE. Ms. Schrammel’s experience includes senior-level positions at major CROs, where she designed and managed late phase programs including patient registries, clinical-experience trials, pharmacoeconomic trials, and managed-care-based effectiveness trials.

Neal Mantick will serve as senior director of Global Observational Research. Mr. Mantick has more than 25 years of experience in the pharmaceutical and biotech industries. Prior to joining the company, he served as an executive director at Abt Bio-Pharma Solutions, Inc., where he led the Observational Studies/Registries Business Unit. Previously at Genzyme, he was responsible for ongoing management of four global registries for rare diseases.

David Brown, Ph.D., has been appointed vice president of Epidemiology. Dr. Brown most recently served as senior director of Epidemiology at King Pharmaceuticals. Prior to joining King, he held senior positions in epidemiology and global safety surveillance, including serving as epidemiology team leader for oncology and neurosciences at Wyeth Research.

Deborah Lubeck , Ph.D., will serve as vice president of Health Economics and Outcomes Research. Prior to joining the company, Dr. Lubeck served as vice president of Late Phase Services at a major CRO. Previously, she was a member of the research faculty at Stanford University and the University of California, San Francisco. Her research has focused on the design and analysis of observational studies, including in the infectious disease, oncology, metabolism/endocrine and musculoskeletal therapeutic areas.

“Observational research has become increasingly important as a means to demonstrate product value in a real world clinical setting,” said Carol Collins, Ph.D., corporate vice president and worldwide head of PACE at PAREXEL. “These appointments to the PAREXEL PACE global team of late phase experts add extensive expertise to help clients optimize the design and execution of their late phase and observational research programs to seamlessly move products from clinical development through commercialization.”